Unaudited Interim Results to 30 June 2025
RNS Announcements
New Commercial Partnership in Mexico
10 October 2024
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to
support cardiometabolic health, is pleased to announce a new commercial partnership
with Mexico based raw materials and ingredients specialist Raff.
Founded in 1999, Raff is a distributor of raw materials and value-added ingredients,
with a particular focus on the dairy and nutraceutical sectors. Backed by a highly
trained technical team, Raff specialises in the use and application of lactic and
probiotic cultures, rennet, enzymes and preservatives.
Mexico has a population of 131 million people, with cardiovascular disease the single
largest killer, accounting for nearly 24% of all deaths. Moreover, it is estimated
that around 3.6 million people die in Mexico every year from high cholesterol. The
movement from ‘cure' towards ‘prevention' provides a strong backdrop for the
fast-growing supplement market, which should lead to a good sales opportunity for
ProBiotix.
The five-year agreement enables Raff to act in partnership with ProBiotix, as the
exclusive distributor of LPLDL® to be used as an ingredient
for the local manufacturing of finished products. The launch is planned for the
first half of 2025, with commercial sales expected in late 2025/early 2026.
Steen Andersen, CEO of ProBiotix, commented: “After lengthy
discussions we are delighted to announce our partnership with Raff and firmly
believe that they share our ethos – to develop innovative products to help
enrich individuals with healthier lives.
“The cardiovascular drug market in Mexico is estimated to be worth $2.2 billion
this year, and provides a huge latent opportunity. With an ageing population, we
believe Mexico provides a highly attractive market for ProBiotix to
target.”
Rafael Gonzalez, Commercial Director of Raff, added: “As an already
well established probiotics supplier in the Mexican market through our
relationship with Italy based Sacco Systems, having the opportunity to partner
with ProBiotix Health, being a pioneer within probiotics and cardiometabolic
health, is extremely exciting for us.
“We welcome the opportunity to expand our portfolio with a unique well documented precision biotic like LPLDL®. It is our belief that LPLDL® fills an untapped potential in the fast growing Mexican supplement market, and that the product sits well with our already strong position in the sector.”
For further information, please contact:
ProBiotix Health plc | https://probiotixhealth-ir.com/ |
Steen Andersen, Chief Executive Officer | Contact via Walbrook below |
Peterhouse Capital Limited (Aquis Corporate Adviser and Broker) | |
Mark Anwyl |
Tel: 020 7220 9793 |
Walbrook PR Ltd | probiotix@walbrookpr.com |
Anna Dunphy | Mob: 07876 741 001 |
Aquis-listed ProBiotix Health
taps into demand for
cardiovascular disease treatments
Stephen O'Hara | 23
February 2023
IG UK | Youtube